Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
7.28% $8.25
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 506.45 mill |
EPS: | -3.16 |
P/E: | -2.61 |
Earnings Date: | May 16, 2024 |
SharesOutstanding: | 61.39 mill |
Avg Daily Volume: | 1.475 mill |
RATING 2024-03-27 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.61 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.44x |
Company: PE -2.61 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.474 (-82.13%) $-6.78 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 7.75 - 8.75 ( +/- 6.05%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-16 | Xynos Konstantinos | Sell | 7 313 | Common Stock |
2023-11-16 | Sarchi Christopher | Sell | 5 255 | Common Stock |
2023-09-18 | Hill Emily Luisa | Buy | 125 000 | Employee Stock Option (right to buy) |
2023-09-18 | Hill Emily Luisa | Buy | 83 330 | Common Stock |
2023-09-18 | Hill Emily Luisa | Buy | 0 |
INSIDER POWER |
---|
54.14 |
Last 98 transactions |
Buy: 2 285 388 | Sell: 489 465 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $8.25 (7.28% ) |
Volume | 0.991 mill |
Avg. Vol. | 1.475 mill |
% of Avg. Vol | 67.15 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $7.81 | N/A | Active |
---|
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.